Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
P/B ratio for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
P/B ratio as of 2023: 6.14
According to Sun Pharmaceutical Industries Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.14. At the end of 2022 the company had a P/B ratio of 4.21.
P/B ratio history for Sun Pharmaceutical Industries Limited from 2003 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 6.14 |
| 2022 | 4.21 |
| 2021 | 4.57 |
| 2020 | 3.09 |
| 2019 | 1.87 |
| 2018 | 2.77 |
| 2017 | 3.20 |
| 2016 | 4.51 |
| 2015 | 6.28 |
| 2014 | 9.60 |
| 2013 | 6.43 |
| 2012 | 5.62 |
| 2011 | 4.85 |
| 2010 | 4.83 |
| 2009 | 4.74 |
| 2008 | 3.27 |
| 2007 | 4.91 |
| 2006 | 7.16 |
| 2005 | 10.03 |
| 2004 | 7.65 |
| 2003 | 3.71 |